Minnie Baylor-Henry,
JD
President, B-Henry & Associates
Minnie Baylor-Henry recently served as Worldwide Vice President for Regulatory Affairs, Johnson & Johnson. She has served as Consultant in the Life Sciences Regulatory Practice at Deloitte & Touche LLP based on her extensive expertise as Johnson & Johnson Vice President for Global Regulatory Affairs, Over the Counter products; and as Senior Director, Regulatory Affairs. Before joining Johnson & Johnson, Minnie served as the US Food and Drug Administration Director of the Division of Drug Marketing, Advertising, and Communications, and as the US Food and Drug Administration’s National Health Fraud Coordinator. A pharmacist and an attorney, Minnie received her pharmacy degree from Howard University and her JD from Catholic University. She has been a longtime member of DIA and has served as President of the DIA Board.
Fellows of DIA
-
Tatsuo Kurokawa,
PhD •Chair, Fellows of DIA
President, Japan Self-Medication Industry -
Martin Harvey Allchurch • Principal International Affairs Officer, European Medicines Agency, European Union
-
Minnie Baylor-Henry,
JD • President, B-Henry & Associates -
Gaby Danan,
MD, PhD • Pharmacovigilance Expert -
Richard Day,
MD • Professor of Clinical Pharmacology, St. Vincent's Hospital -
Marie Dray,
MBA • President, International Regulatory Affairs Group LLC -
Nancy A. Dreyer,
MPH, PhD • Global Chief, Sci Affairs; Sr VP, Head, Center for Advanced Evidence Generation
IQVIA -
Ron Fitzmartin,
PhD • Senior Advisor, Strategic Programs,Center for Drug Evaluation and Research, US Food and Drug Administration -
E. Stewart Geary,
MD • Senior VP, Chief Medical Officer, Director, Corporate Medical Affairs HQ, Eisai Co., Ltd. -
Ken Getz,
MBA • Chairman, CISCRP; Director of Sponsored Research, Tufts Center For the Study of Drug Development -
Alberto Grignolo,
PhD • Corporate Vice President
PAREXEL International -
Yves Juillet,
MD • Senior Vice-President, Industrie Sante -
Sandra L. Kweder,
MD • Deputy Director, FDA Liaison to the EMA, Office of International Programs, OC -
Murray M. Lumpkin,
MD • Deputy Director, Integrated Delivery, and Lead for Global Regulatory Systems Initiatives
Bill and Melinda Gates Foundation -
Sandra A. Milligan,
MD, JD • Senior Vice President, Head of Global Regulatory Affairs and Clinical Safety, Merck & Co., Inc. -
Noriaki Murao,
MS • Representative, NM Consulting -
Jennifer Riggins,
PhD • Advisor, Digital Channels and eCapabilities, Eli Lilly and Company -
Jeffrey Sherman,
MD • Chief Medical Officer & EVP, Horizon Pharma, Inc. -
Per Spindler,
DVM, MBA • Director Biopeople, University of Copenhagen -
Ling Su,
PhD • Professor and Director, Institute of Drug Regulatory Science, Shenyang Pharmaceutical University, Venture Partner, Lilly Asia Ventures